-

$undefined

N/A

(N/A)

SELLAS Life Sciences Group NASDAQ:SLS SELLAS is a late-stage clinical biopharmaceutical company focused on the development of novel cancer immunotherapeutics for a broad range of cancer indications. SELLAS' lead product candidate, GPS, is licensed from Memorial Sloan Kettering Cancer Center and targets the WT1 protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination to address a broad spectrum of hematologic malignancies and solid tumor indications. SELLAS' second product candidate, NPS, is a HER2-directed cancer immunotherapy with potential for the treatment of patients with early-stage breast cancer with low to intermediate HER2 expression, otherwise known as HER2 1+ or 2+, which includes triple negative breast cancer patients, following standard of care.

Location: 2140 S Dupont Hwy, Delaware, 19934-1249, US | Website: www.sellaslifesciences.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing

Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

68.93M

Cash

21.03M

Avg Qtr Burn

-8.269M

Short % of Float

13.99%

Insider Ownership

0.17%

Institutional Own.

9.36%

Qtr Updated

09/30/24

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Galinpepimut-S Details Blood cancer, Cancer, Acute myeloid leukemia	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
SLS009 (GFH009) +/- venetoclax & azacitidine Details Blood cancer, Cancer, Acute myeloid leukemia, Lymphoma	Phase 2a Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
SLS009 (GFH009) + Brukinsa Details Cancer, Blood cancer, Diffuse large B cell lymphoma	Phase 2a Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Galinpepimut-S + KEYTRUDA (pembrolizumab) Details Ovarian cancer, Solid tumor/s, Cancer	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
SLS009 (GFH009) Details Blood cancer, Cancer, Lymphoma, Peripheral T-cell Lymphomas	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
SLS009 (GFH009) Details Cancer, Blood cancer, Pediatric Sarcomas	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Galinpepimut-S + OPDIVO (nivolumab) Details Cancer, Malignant pleural/peritoneal mesothelioma	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Nelipepimut-S Details Solid tumor/s, Cancer, Breast cancer, Triple-negative breast cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.